Clear All
720 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 Jul 1, 2020 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
Q5119 Rituximab-pvvr Ruxience 10mg Immunotherapy Monoclonal Antibody CD20 No 2019 Jul 1, 2020 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J1456 Fosaprepitant (Teva) Fosaprepitant (Teva) 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2019 Dec 21, 2022 In Use
J9304 Pemetrexed Pemfexy 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2020 Oct 1, 2020 In Use
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan 1, 2021 In Use
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan 1, 2021 In Use
NA Pilocarpine Hydrochloride Pilocarpine 5mg, 10mg Ancillary Therapy Miscellaneous Agent Cholinergic Agent Yes 2020 In Use
C9062 Daratumumab Hyaluronidase Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 Jan 1, 2021 No Longer Used
NA Ripretinib Qinlock 50mg Chemotherapy Tyrosine Kinase Inhibitor KIT, PDGFRA Yes 2020 In Use
J9227 Isatuximab-irtc Sarclisa 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 In Use
J9223 Lurbinectedin Zepzelca 0.1mg Chemotherapy Alkylating Agent Adduct Forming Agent No 2020 Jan 1, 2021 In Use
NA Selumetinib Koselugo 10mg, 25mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2020 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Pralsetinib Gavreto 100mg Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Yes 2020 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
Q2053 Brexucabtagene autoleucel Tecartus 2000000 Immunotherapy CAR-T CD-19 No 2020 Apr 1, 2021 In Use
C9073 Brexucabtagene autileucel Tecartus 2000000 Immunotherapy CAR-T CD19 No 2020 Jan 1, 2021 Apr 1, 2021 In Use
J9073 Cyclophosphamide (ingenus) Cyclophosphamide (ingenus) 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2020 Apr 17, 2024 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.